255 related articles for article (PubMed ID: 20822354)
1. Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis.
Herbrecht R; Rajagopalan S; Danna R; Papadopoulos G
Curr Med Res Opin; 2010 Oct; 26(10):2457-64. PubMed ID: 20822354
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic assessment of therapy for invasive aspergillosis.
Luong ML; Husain S; Rotstein C
Mycoses; 2013 May; 56(3):338-49. PubMed ID: 23311989
[TBL] [Abstract][Full Text] [Related]
3. [Cost effectiveness of posaconazole versus fluconazole/itraconazole in the prophylactic treatment of invasive fungal infections in Mexico].
Rely K; Alexandre PK; Escudero GS
Value Health; 2011; 14(5 Suppl 1):S39-42. PubMed ID: 21839897
[TBL] [Abstract][Full Text] [Related]
4. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.
Wingard JR; Herbrecht R; Mauskopf J; Schlamm HT; Marciniak A; Roberts CS
Transpl Infect Dis; 2007 Sep; 9(3):182-8. PubMed ID: 17605747
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A
Value Health; 2006; 9(1):12-23. PubMed ID: 16441520
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation.
Sánchez-Ortega I; Patiño B; Muñoz C; Arnan M; Peralta T; Clopés A; de Sevilla AF; Duarte RF
J Med Econ; 2013; 16(6):736-43. PubMed ID: 23541251
[TBL] [Abstract][Full Text] [Related]
7. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
Walsh TJ; Raad I; Patterson TF; Chandrasekar P; Donowitz GR; Graybill R; Greene RE; Hachem R; Hadley S; Herbrecht R; Langston A; Louie A; Ribaud P; Segal BH; Stevens DA; van Burik JA; White CS; Corcoran G; Gogate J; Krishna G; Pedicone L; Hardalo C; Perfect JR
Clin Infect Dis; 2007 Jan; 44(1):2-12. PubMed ID: 17143808
[TBL] [Abstract][Full Text] [Related]
8. An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States.
Sung AH; Marcella SW; Xie Y
J Med Econ; 2015 May; 18(5):341-8. PubMed ID: 25524741
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
[TBL] [Abstract][Full Text] [Related]
10. Adapting a global cost-effectiveness model to local country requirements: posaconazole case study.
Papadopoulos G; Hunt S; Prasad M
J Med Econ; 2013; 16(3):374-80. PubMed ID: 23256900
[TBL] [Abstract][Full Text] [Related]
11. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study.
Slobbe L; Polinder S; Doorduijn JK; Lugtenburg PJ; el Barzouhi A; Steyerberg EW; Rijnders BJ
Clin Infect Dis; 2008 Dec; 47(12):1507-12. PubMed ID: 18990068
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium.
Selleslag D; Vogelaers D; Marbaix S
Acta Clin Belg; 2009; 64(5):393-8. PubMed ID: 19999386
[TBL] [Abstract][Full Text] [Related]
13. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece.
Athanasakis K; Petrakis I; Kyriopoulos J
J Med Econ; 2013; 16(5):678-84. PubMed ID: 23448409
[TBL] [Abstract][Full Text] [Related]
15. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
Stam WB; O'Sullivan AK; Rijnders B; Lugtenburg E; Span LF; Janssen JJ; Jansen JP
Eur J Haematol; 2008 Dec; 81(6):467-74. PubMed ID: 18754857
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats.
Ullmann AJ; Krammes E; Sommer S; Buschmann I; Jahn-Muehl B; Cacciapuoti A; Schmitt HJ
J Antimicrob Chemother; 2007 Nov; 60(5):1080-4. PubMed ID: 17855727
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
[TBL] [Abstract][Full Text] [Related]
20. Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand?
Garbino J; Schnetzler G; Roberts C
Swiss Med Wkly; 2006 Sep; 136(39-40):624-30. PubMed ID: 17086508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]